Niagen Bioscience, Inc.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net Income (Loss) Attributable to Parent ($2.9m) ($11.4m) ($33.3m) ($32.1m) ($19.9m) ($27.1m) ($16.5m) ($4.9m) $8.6m $17.4m
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent ($16.5m) ($33.3m)
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest $5.2m $0
Depreciation, Depletion and Amortization $332k $510k $607k $762k $871k $890k $869k $870k $663k $612k
Depreciation $332k $510k $607k $762k $871k $890k $869k $870k $663k $612k
Amortization of Debt Issuance Costs ($15k) ($75k) ($19k) $846k ($49k) ($110k) ($77k) ($75k) ($52k) ($67k)
Amortization of Debt Issuance Costs and Discounts ($15k) ($75k) ($19k) ($113k) $0 ($110k) ($77k) ($75k) ($52k) ($67k)
Amortization of Intangible Assets $88k $206k $235k $246k $243k $225k $186k $158k $151k $173k
Deferred Income Tax Expense (Benefit) $0 $0 $0
Share-based Payment Arrangement, Noncash Expense $1.2m $4.6m $6.4m $7.2m $6.9m $6.2m $5.7m $4.8m $3.7m $6.1m
Share-based Payment Arrangement, Expense $1.2m $4.6m $6.4m $7.2m
Goodwill, Impairment Loss $0
Impairment of Intangible Assets (Excluding Goodwill) $0
Impairment of Intangible Assets, Finite-lived $4k $0 $3k $0
Share-based Payment Arrangement, Expensed and Capitalized, Amount $1.3m
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property ($7k) ($5.5m) $0 ($553k) $0 $7k ($5k) ($19k) $4k
Gain (Loss) on Disposition of Intangible Assets $117k
Gain (Loss) on Disposition of Property Plant Equipment ($5k) ($1k) ($7k) $0 ($7k) $5k $19k ($4k)
Gain (Loss) on Extinguishment of Debt ($313k) $0 ($65k)
Income Tax Expense (Benefit) $0 $0 $305k $810k
Operating Lease, Expense $663k $501k $1.1m $1.3m $1.2m $1.3m $1.3m
Changes in operating assets and liabilities:
Additional Financial Items
Increase (Decrease) in Inventories ($241k) $2.2m ($2.5m) ($3.3m) ($148k) $1.9m $1.1m ($152k) ($5.3m) $11.6m
Increase (Decrease) in Accounts Payable ($246k) ($2.4m) $5.8m $78k ($181k) $978k ($744k) $553k ($1.1m) $2.3m
Proceeds from Stock Options Exercised $717k $3.0m $529k $1.1m $4.1m $9.5m $0 $0 $5.4m $7.2m
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal $7k $5.5m $0 $7k $0 $7k ($5k) ($19k) $4k
Gain (Loss) Related to Litigation Settlement ($746k) ($746k) $2.0m
General and Administrative Expense $9.4m $17.6m $27.1m $34.3m $30.4m $36.4m $28.3m $25.0m $18.4m $27.1m
Investment Income, Interest $2k $2.1m
Nonoperating Income (Expense) ($683k) ($153k) ($144k) ($847k) ($71k)
Operating Expenses $14.2m $26.9m $49.2m $57.1m $55.1m $68.6m $61.4m $56.4m $53.9m $66.9m
Payments of Financing Costs $110k
Net Cash Provided by (Used in) Operating Activities ($2.9m) ($9.8m) ($20.9m) ($20.4m) ($10.6m) ($24.2m) ($15.1m) $7.1m $12.1m $13.5m
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $1.5m $1.2m $1.3m $743k $47k $0 $334k $148k $163k $292k
Payments to Acquire Investments $49k
Net Cash Provided by (Used in) Investing Activities ($1.7m) $4.6m ($1.8m) ($249k) ($165k) ($409k) ($334k) ($143k) ($143k) ($292k)
Cash flows from financing activities:
Proceeds from Issuance of Common Stock $5.7m $46.6m $0 $6.8m $4.9m $26.7m $7.7m $0
Payments for Repurchase of Common Stock $0 $404k $0 $0 $251k
Net Cash Provided by (Used in) Financing Activities $754k $48.9m ($90k) $16.9m $8.7m $36.1m $7.7m ($90k) $5.4m $6.9m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect ($2.1m) $11.5m ($7.8m) $6.9m $17.3m $20.1m
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $18.8m $16.7m $28.2m $20.4m $27.3m $44.7m $64.8m
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities $57k $41k $33k $13k $1k $1k $2k $1k $1k